Page 8 - Singular Genomics News Today

Three life science companies went public in the last full week of May. The biggest IPO belonged to Centessa Pharmaceuticals, a company that raised $330 million to support its unconventional but not unprecedented approach to drug R&D.

Print Singular Genomics, a San Diego startup that’s developing next-generation sequencing technology for oncology and immunology, has filed a prospectus to become a publicly traded company. Founded in 2016, Singular hasn’t disclosed yet how much money it hopes to raise or the proposed price range of its shares. That information should be revealed as Singular gets closer to pricing its initial public stock offering. But it is attempting an IPO at a time when investors are receptive to bettin...